Sobi Highlights Gamifant Efficacy with New HLH Data at HS2026

  • Sobi will present new clinical data on Gamifant (emapalumab) at the 2026 Histiocyte Society Annual Meeting in Rotterdam.
  • Key presentations include a pooled analysis of survival outcomes across three trials and data from a post-authorization study in Chinese patients.
  • One poster nominated for the Robert J. Arceci Prize for Best Poster, signaling strong scientific recognition.
  • Gamifant is the only approved anti-interferon gamma monoclonal antibody for primary HLH and related conditions.

Sobi's focus on expanding Gamifant's clinical evidence aligns with broader trends in rare disease therapeutics, where robust data packages are critical for market access and payer negotiations. The company's emphasis on transplant outcomes and global patient populations reflects a strategic push to position Gamifant as a cornerstone treatment across diverse HLH patient subgroups. With revenue approaching SEK 28 billion, Sobi's ability to leverage these data could drive further growth in its specialty portfolio.

Clinical Validation
Whether the pooled survival data will strengthen Gamifant's position as a frontline therapy for primary HLH.
Market Expansion
How the Chinese patient data may accelerate regulatory approvals or commercialization in Asia.
Competitive Dynamics
The pace at which Sobi can differentiate Gamifant in an increasingly crowded rare disease space.